

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10579049
	Filing Date		2008-09-18
	First Named Inventor	C. Garrison Fathman	
	Art Unit	1639	
	Examiner Name		
Attorney Docket Number		STAN-324	

U.S.PATENTS							Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1						

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S.PATENT APPLICATION PUBLICATIONS							Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1						

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

FOREIGN PATENT DOCUMENTS								Remove
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button.

Add

NON-PATENT LITERATURE DOCUMENTS			Remove
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10579049
Filing Date		2008-09-18
First Named Inventor	C. Garrison Fathman	
Art Unit	1639	
Examiner Name		
Attorney Docket Number	STAN-324	

1	ANANDASABAPATHY; et al., "GRAIL: An E3 Ubiquitin Ligase that Inhibits Cytokine Gene Transcription is Expressed in Anergic CD4+T Cells", Immunity, April 2003, 18:535-547.	<input type="checkbox"/>
2	BALAKIREV; et al., "Otubains: a new family of cysteine proteases in the ubiquitin pathway", EMBO Reports, April 2003, 4(5):517-522.	<input type="checkbox"/>
3	GNESUTTA; et al., "Cloning and Characterization of Mouse UBPY, a Deubiquitinating Enzyme That Interacts with the Ras Guanine Nucleotide Exchange Factor CDC25Mm/Ras-GRF1" J. Biol. Chem (2001), 276(42):39448-39454.	<input type="checkbox"/>
4	KATO; et al., "A Deubiquitinating Enzyme UBPY Interacts with the Src Homology 3 Domain of Hrs-binding Protein via a Novel Binding Motif PX(V/I)(D/N) RXXKP" J. Biol. Chem (2000), 275(48):37481-37487.	<input type="checkbox"/>
5	NANAO; et al., "Crystal structure of human otubain 2", EMBO Reports, July 2004, 5(8):783-788.	<input type="checkbox"/>
6	NAVIGLIO; et al., "UBPY: a growth-regulated human ubiquitin isopeptidase" The EMBO Journal (1998), 17 (12):3241-3250.	<input type="checkbox"/>
7	SEROOGY; et al., "The Gene Related to Anergy in Lymphocytes, an E3 Ubiquitin Ligase, Is Necessary for Anergy Induction in CD4 T Cells", The Journal of Immunology (2004), 173:79-85.	<input type="checkbox"/>
8	SOARES; et al., "Two isoforms of otubain 1 regulate T cell anergy via GRAIL", Nature Immunology, January 2004, 5 (1):45-54.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.